

Response to: ‘Correspondence on ‘Risk of venous thromboembolism in rheumatoid arthritis and its association with disease activity: a nationwide cohort study from Sweden’ by Zervou *et al*

We thank the authors for their interest¹ in our article ‘Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden’², and for their effort in identifying genetic factors involved in the pathogenesis of both rheumatoid arthritis (RA) and venous thromboembolism (VTE).

As the authors suggest, identification of additional genetic loci associated with both diseases would be another important step in understanding the reasons behind the increased VTE risk in RA and might also help in identifying patients at particularly increased risk of VTE.

Viktor Molander ^{1,2} **Johan Askling** ^{1,2}

¹Clinical Epidemiology Division, Karolinska Institutet, Stockholm, Sweden

²Rheumatology, Karolinska University Hospital, Stockholm, Sweden

Correspondence to Dr Viktor Molander, Clinical Epidemiology Division, Karolinska Institutet, 171 77 Solna, Sweden; viktor.molander@ki.se

Handling editor Josef S Smolen

Contributors VM and JA contributed to the drafting of the response.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests Karolinska Institutet, with JA as principal investigator, has or has had research agreements with Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer,

Roche, Samsung Bioepis, Sanofi, and UCB, mainly in the context of safety monitoring of biologics via ARTIS/Swedish Biologics Register.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Molander V, Askling J. *Ann Rheum Dis* 2023;**82**:e88.

Received 22 January 2021

Accepted 23 January 2021

Published Online First 1 February 2021



► <http://dx.doi.org/10.1136/annrheumdis-2021-219894>

Ann Rheum Dis 2023;**82**:e88. doi:10.1136/annrheumdis-2021-219920

ORCID iDs

Viktor Molander <http://orcid.org/0000-0003-0087-2565>

Johan Askling <http://orcid.org/0000-0003-0433-0616>

REFERENCES

- 1 Zervou MI, Goulielmos GN. Correspondence on “Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.” *Ann Rheum Dis* 2023;**82**:e87.
- 2 Molander V, Bower H, Frisell T, *et al*. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. *Ann Rheum Dis* 2021;**80**:169–75.